A multigene array for measurable residual disease detection in AML patients undergoing SCT

M. Goswami, K. S. McGowan, K. Lu, N. Jain, J. Candia, N. F. Hensel, J. Tang, K. R. Calvo, M. Battiwalla, A. J. Barrett, C. S. Hourigan

Research output: Contribution to journalArticlepeer-review


AML is a diagnosis encompassing a diverse group of myeloid malignancies. Heterogeneous genetic etiology, together with the potential for oligoclonality within the individual patient, have made the identification of a single high-sensitivity marker of disease burden challenging. We developed a multiple gene measurable residual disease (MG-MRD) RQ-PCR array for the high-sensitivity detection of AML, retrospectively tested on 74 patients who underwent allo-SCT at the NHLBI in the period 1994-2012. MG-MRD testing on peripheral blood samples prior to transplantation demonstrated excellent concordance with traditional BM-based evaluation and improved risk stratification for post-transplant relapse and OS outcomes. Pre-SCT assessment by MG-MRD predicted all clinical relapses occurring in the first 100 days after allo-SCT compared with 57% sensitivity using WT1 RQ-PCR alone. Nine patients who were negative for WT1 prior to transplantation were correctly reclassified into a high-risk MG-MRD-positive group, associated with 100% post-transplant mortality. This study provides proof of principle that a multiple gene approach may be superior to the use of WT1 expression alone for AML residual disease detection.

Original languageEnglish (US)
Pages (from-to)642-651
Number of pages10
JournalBone marrow transplantation
Issue number5
StatePublished - May 8 2015
Externally publishedYes

ASJC Scopus subject areas

  • Hematology
  • Transplantation


Dive into the research topics of 'A multigene array for measurable residual disease detection in AML patients undergoing SCT'. Together they form a unique fingerprint.

Cite this